1. Home
  2. STE vs BIIB Comparison

STE vs BIIB Comparison

Compare STE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STERIS plc (Ireland)

STE

STERIS plc (Ireland)

HOLD

Current Price

$214.72

Market Cap

22.3B

Sector

Health Care

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.32

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STE
BIIB
Founded
1985
1978
Country
United States
United States
Employees
3700
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3B
27.1B
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
STE
BIIB
Price
$214.72
$183.32
Analyst Decision
Buy
Buy
Analyst Count
6
27
Target Price
$275.20
$194.72
AVG Volume (30 Days)
846.3K
827.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.19%
N/A
EPS Growth
62.73
N/A
EPS
5.69
8.79
Revenue
$5,459,515,000.00
$9,890,600,000.00
Revenue This Year
$9.88
N/A
Revenue Next Year
$6.32
N/A
P/E Ratio
$37.42
$21.03
Revenue Growth
6.24
2.22
52 Week Low
$204.90
$110.04
52 Week High
$269.44
$202.41

Technical Indicators

Market Signals
Indicator
STE
BIIB
Relative Strength Index (RSI) 24.65 46.95
Support Level N/A $181.24
Resistance Level $254.67 $186.17
Average True Range (ATR) 5.90 5.30
MACD -3.20 -1.14
Stochastic Oscillator 11.00 16.93

Price Performance

Historical Comparison
STE
BIIB

About STE STERIS plc (Ireland)

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: